Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy.
10.3779/j.issn.1009-3419.2022.102.19
- Author:
Lin JIANG
1
;
Jingbo ZHANG
1
;
Jiaqi HU
1
;
Haixiang QI
1
;
Heng XU
1
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China.
- Publication Type:Journal Article
- Keywords:
ALK;
EGFR;
KRAS;
Lung neoplasms;
Proteolysis targeting chimeria
- MeSH:
Carcinoma, Non-Small-Cell Lung/pathology*;
Humans;
Lung Neoplasms/pathology*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Proteolysis;
Proto-Oncogene Proteins p21(ras)/genetics*
- From:
Chinese Journal of Lung Cancer
2022;25(7):477-481
- CountryChina
- Language:Chinese
-
Abstract:
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC.
.
